Obefazimod
Phase 2Recruiting 1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Moderately to Severely Active Crohn Disease
Conditions
Moderately to Severely Active Crohn Disease
Trial Timeline
Oct 30, 2024 → Apr 1, 2028
NCT ID
NCT06456593About Obefazimod
Obefazimod is a phase 2 stage product being developed by Abivax for Moderately to Severely Active Crohn Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06456593. Target conditions include Moderately to Severely Active Crohn Disease.
What happened to similar drugs?
0 of 7 similar drugs in Moderately to Severely Active Crohn Disease were approved
Approved (0) Terminated (0) Active (7)
Hype Score Breakdown
Clinical
12
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06456593 | Phase 2 | Recruiting |
Competing Products
7 competing products in Moderately to Severely Active Crohn Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CT-P13 SC Auto-Injector + Placebo Auto-Injector | Celltrion | Phase 3 | 44 |
| Afimkibart + Placebo | Chugai Pharmaceutical | Phase 3 | 47 |
| Afimkibart + Placebo | Chugai Pharmaceutical | Phase 3 | 44 |
| Afimkibart + Placebo | Chugai Pharmaceutical | Phase 3 | 47 |
| Afimkibart + Placebo | Roche | Phase 3 | 47 |
| Afimkibart | Roche | Phase 3 | 47 |
| Afimkibart | Roche | Phase 3 | 47 |